Second Biogen Idec collaboration gives Isis up to $271 million plus royalties
This article was originally published in Scrip
Executive Summary
Barely six months into their first partnership, Isis Pharmaceuticals and Biogen Idec signed an exclusive, worldwide option and collaboration agreement worth $12 million up front to develop a novel antisense drug for the treatment of myotonic dystrophy type 1 (DM1), also known as Steinert disease.